INTRODUCTION: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (rdf) in the prophylaxis of radiation-induced nausea and vomiting (rinv). Rapidly dissolving film formulations facilitate drug delivery in circumstances in which swallowing the medication might be difficult for the patient. METHODS:Patients undergoing palliative radiotherapy at risk for rinv were prescribedondansetron rdf 8 mg twice daily while on treatment and were asked to complete a nausea and vomiting-specific daily diary, the Functional Living Index-Emesis (flie), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C15 Palliative (qlq-C15-pal). Patients were categorized as receiving primary or secondary prophylaxis based on whether they had already experienced emetic episodes. "Overall control" was defined as a maximum increase of 2 episodes of nausea or vomiting from baseline. "Acute phase" was defined as the days during radiation until the first day after radiation; "delayed phase" was defined as days 2-10 after radiation. RESULTS: The study accrued 30 patients. Rates of overall control for nausea and for vomiting during the acute phase in the primary prophylaxis group were 88% and 93% respectively; during the delayed phase, they were 73% and 75%. Rates of overall control for nausea and for vomiting during the acute phase in the secondary prophylaxis group were both 100%; during the delayed phase, they were 50%. The number of nausea and vomiting episodes was found to be significantly correlated with the flie and qlq-C15-pal questionnaires. CONCLUSIONS:Ondansetron rdf is effective for the prophylaxis of rinv.
RCT Entities:
INTRODUCTION: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (rdf) in the prophylaxis of radiation-induced nausea and vomiting (rinv). Rapidly dissolving film formulations facilitate drug delivery in circumstances in which swallowing the medication might be difficult for the patient. METHODS:Patients undergoing palliative radiotherapy at risk for rinv were prescribed ondansetron rdf 8 mg twice daily while on treatment and were asked to complete a nausea and vomiting-specific daily diary, the Functional Living Index-Emesis (flie), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C15 Palliative (qlq-C15-pal). Patients were categorized as receiving primary or secondary prophylaxis based on whether they had already experienced emetic episodes. "Overall control" was defined as a maximum increase of 2 episodes of nausea or vomiting from baseline. "Acute phase" was defined as the days during radiation until the first day after radiation; "delayed phase" was defined as days 2-10 after radiation. RESULTS: The study accrued 30 patients. Rates of overall control for nausea and for vomiting during the acute phase in the primary prophylaxis group were 88% and 93% respectively; during the delayed phase, they were 73% and 75%. Rates of overall control for nausea and for vomiting during the acute phase in the secondary prophylaxis group were both 100%; during the delayed phase, they were 50%. The number of nausea and vomiting episodes was found to be significantly correlated with the flie and qlq-C15-pal questionnaires. CONCLUSIONS:Ondansetron rdf is effective for the prophylaxis of rinv.
Entities:
Keywords:
Radiation-induced nausea and vomiting; ondansetron; prophylaxis; rapidly dissolving film
Authors: Kristopher Dennis; Liying Zhang; Stephen Lutz; Angela van Baardwijk; Yvette van der Linden; Tanya Holt; Palmira Foro Arnalot; Jean-Léon Lagrange; Ernesto Maranzano; Rico Liu; Kam-Hung Wong; Lea-Choung Wong; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-15 Impact factor: 7.038
Authors: Kristopher Dennis; Liying Zhang; Stephen Lutz; Yvette van der Linden; Angela van Baardwijk; Tanya Holt; Jean-Leon Lagrange; Palmira Foro-Arnalot; Lea-Choung Wong; Ernesto Maranzano; Kam-Hung Wong; Rico Liu; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2013-02-26 Impact factor: 3.603
Authors: Kristopher Dennis; Janet Nguyen; Roseanna Presutti; Carlo DeAngelis; May Tsao; Cyril Danjoux; Elizabeth Barnes; Arjun Sahgal; Lori Holden; Florencia Jon; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2011-09-08 Impact factor: 3.603
Authors: Petra Christine Feyer; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Rebecca A Clark-Snow; Karin Jordan Journal: Support Care Cancer Date: 2010-08-10 Impact factor: 3.603
Authors: Kristopher Dennis; Ernesto Maranzano; Carlo De Angelis; Lori Holden; Shun Wong; Edward Chow Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2011-12 Impact factor: 2.217
Authors: Rebecca K S Wong; Nancy Paul; Keyue Ding; Marlo Whitehead; Michael Brundage; Anthony Fyles; Derek Wilke; Abdenour Nabid; Andre Fortin; Don Wilson; Michael McKenzie; Ida Ackerman; Luis Souhami; Pierre Chabot; Joseph Pater Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Kavita V Dharmarajan; Shayna E Rich; Candice A Johnstone; Lauren M Hertan; Randy Wei; Lauren E Colbert; Joshua A Jones; Arif H Kamal; Christopher A Jones Journal: J Palliat Med Date: 2018-02-12 Impact factor: 2.947
Authors: Caitlin Yee; Leah Drost; Liying Zhang; Bo Angela Wan; Vithusha Ganesh; May Tsao; Elizabeth Barnes; Mark Pasetka; Carlo DeAngelis; Edward Chow Journal: Support Care Cancer Date: 2018-05-28 Impact factor: 3.603